Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia

[1]  H. Dombret,et al.  Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. , 2004, Blood.

[2]  S. Fröhling,et al.  CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Caligiuri,et al.  BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. , 2003, Blood.

[4]  J. Bourhis,et al.  Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. , 2003, Blood.

[5]  H. Dombret,et al.  Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. , 2003, Blood.

[6]  Bob Löwenberg,et al.  High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. , 2003, Blood.

[7]  Bob Löwenberg,et al.  Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. , 2003, The hematology journal : the official journal of the European Haematology Association.

[8]  J. Cayuela,et al.  Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). , 2002, Blood.

[9]  S. Fröhling,et al.  Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Goldstone,et al.  The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial , 2002, British journal of haematology.

[11]  Martin Dugas,et al.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. , 2002 .

[12]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[13]  H. Dombret,et al.  A white blood cell index as the main prognostic factor in t ( 8 ; 21 ) acute myeloid leukemia ( AML ) : a survey of 161 cases from the French AML Intergroup , 2002 .

[14]  W. Hiddemann,et al.  Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities , 2000, Leukemia.

[15]  T. Naoe,et al.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. , 1999, Blood.

[16]  F. Appelbaum,et al.  Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. , 1998, The New England journal of medicine.

[17]  F. Mandelli,et al.  The influence of HLA‐matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA , 1998, British journal of haematology.

[18]  P. Hurteloup,et al.  Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). , 1997, Blood.

[19]  K. Laczika,et al.  Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study , 1996, Annals of Hematology.

[20]  P. Fenaux,et al.  Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[22]  F. Mitelman.  ISCN 1991 : guidelines for cancer cytogenetics : supplement to An international system for human cytogenetic nomenclature : recommendations of the Standing Committee on Human Cytogenetic Nomenclature, Subcommittee on Cancer Cytogenetics , 1992 .

[23]  C. Bloomfield,et al.  Prognostic factors at relapse for adults with acute myeloid leukemia , 1990, American journal of hematology.

[24]  R. Eddy,et al.  International System for Cytogenetic Nomenclature (ISCN) — guidelines on cancer cytogenetics , 1990 .

[25]  E. Estey,et al.  Response to salvage therapy and survival after relapse in acute myelogenous leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Stijnen,et al.  Treatment of acute myelogenous leukemia. An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation. , 1989, European journal of cancer & clinical oncology.

[27]  H. Kantarjian,et al.  The characteristics and outcome of patients with late relapse acute myelogenous leukemia. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Elashoff,et al.  Treatment of Acute Myelogenous Leukemia: A Prospective Controlled Trial of Bone Marrow Transplantation Versus Consolidation Chemotherapy , 1985 .

[29]  J. Crowley,et al.  Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. , 1984, Annals of internal medicine.

[30]  A. Dewar,et al.  Colchicine in chronic lymphocytic leukemia. , 1984, The New England journal of medicine.

[31]  P. Neiman,et al.  Marrow transplantation for acute nonlymphoblastic leukemia in first remission. , 1979, The New England journal of medicine.